Literature DB >> 22584729

Leiomyoma: genetics, assisted reproduction, pregnancy and therapeutic advances.

Gary Levy1, Micah J Hill, Stephanie Beall, Shvetha M Zarek, James H Segars, William H Catherino.   

Abstract

PURPOSE: Uterine leiomyomas are common, benign, reproductive tract tumors affecting a majority of reproductive aged women. They are associated with gynecologic morbidity and detrimentally affect reproductive potential. The etiology of leiomyomas is poorly understood and their diagnosis prior to treatment with Assisted Reproductive Technologies (ART) represents a management dilemma. The purpose of this paper is to review known genetic and molecular contributions to the etiologies of leiomyomas, describe their impact on ART outcomes and reproductive potential, and review alternative therapies and future directions in management.
METHODS: A critical review of the literature pertaining to genetic component of uterine leiomyomas, their impact on ART and pregnancy and leiomyoma therapeutics was performed.
RESULTS: Uterine leiomyomas are characterized by complex molecular mechanisms. Their location and size determines their potential detriment to ART and reproductive function and novel therapeutic modalities are being developed.
CONCLUSION: The high prevalence of uterine leiomyomas and their potential detrimental influence on ART and reproductive function warrants continued well-designed studies to ascertain their etiology, optimal treatment and novel less morbid therapies.

Entities:  

Mesh:

Year:  2012        PMID: 22584729      PMCID: PMC3430786          DOI: 10.1007/s10815-012-9784-0

Source DB:  PubMed          Journal:  J Assist Reprod Genet        ISSN: 1058-0468            Impact factor:   3.412


  128 in total

1.  Uterine leiomyomas express a molecular pattern that lowers retinoic acid exposure.

Authors:  William H Catherino; Minnie Malik
Journal:  Fertil Steril       Date:  2007-02-02       Impact factor: 7.329

Review 2.  Fibroids and reproductive outcomes: a systematic literature review from conception to delivery.

Authors:  Peter C Klatsky; Nam D Tran; Aaron B Caughey; Victor Y Fujimoto
Journal:  Am J Obstet Gynecol       Date:  2008-04       Impact factor: 8.661

3.  A randomized, controlled trial of asoprisnil, a novel selective progesterone receptor modulator, in women with uterine leiomyomata.

Authors:  Kristof Chwalisz; Lois Larsen; Cynthia Mattia-Goldberg; Anthony Edmonds; Walter Elger; Craig A Winkel
Journal:  Fertil Steril       Date:  2007-02-20       Impact factor: 7.329

4.  Effects of the progesterone receptor modulator VA2914 in a continuous low dose on the hypothalamic-pituitary-ovarian axis and endometrium in normal women: a prospective, randomized, placebo-controlled trial.

Authors:  Nathalie Chabbert-Buffet; Axelle Pintiaux-Kairis; Philippe Bouchard
Journal:  J Clin Endocrinol Metab       Date:  2007-06-19       Impact factor: 5.958

Review 5.  Mechanisms of disease: hereditary leiomyomatosis and renal cell cancer--a distinct form of hereditary kidney cancer.

Authors:  Sunil Sudarshan; Peter A Pinto; Len Neckers; W Marston Linehan
Journal:  Nat Clin Pract Urol       Date:  2007-02

6.  Retinoic acid pathway genes show significantly altered expression in uterine fibroids when compared with normal myometrium.

Authors:  Marina Zaitseva; Beverley J Vollenhoven; Peter A W Rogers
Journal:  Mol Hum Reprod       Date:  2007-06-06       Impact factor: 4.025

Review 7.  Fibroids and female reproduction: a critical analysis of the evidence.

Authors:  E Somigliana; P Vercellini; R Daguati; R Pasin; O De Giorgi; P G Crosignani
Journal:  Hum Reprod Update       Date:  2007-06-21       Impact factor: 15.610

8.  Tumor-specific efficacy of transforming growth factor-beta RI inhibition in Eker rats.

Authors:  Nicholas J Laping; Jeffrey I Everitt; Kendall S Frazier; Mark Burgert; Melisa J Portis; Caprice Cadacio; Leslie I Gold; Cheryl L Walker
Journal:  Clin Cancer Res       Date:  2007-05-15       Impact factor: 12.531

9.  Midterm clinical and first reproductive results of a randomized controlled trial comparing uterine fibroid embolization and myomectomy.

Authors:  Michal Mara; Jana Maskova; Zuzana Fucikova; David Kuzel; Tomas Belsan; Ondrej Sosna
Journal:  Cardiovasc Intervent Radiol       Date:  2007-10-18       Impact factor: 2.740

10.  Genomic and proteomic profiling I: leiomyomas in African Americans and Caucasians.

Authors:  Qun Pan; Xiaoping Luo; Nasser Chegini
Journal:  Reprod Biol Endocrinol       Date:  2007-08-23       Impact factor: 5.211

View more
  20 in total

1.  Injectable Clostridium histolyticum collagenase as a potential treatment for uterine fibroids.

Authors:  Lisa N Brunengraber; Friederike L Jayes; Phyllis C Leppert
Journal:  Reprod Sci       Date:  2014-10-20       Impact factor: 3.060

2.  Matrix production and remodeling as therapeutic targets for uterine leiomyoma.

Authors:  Caitlin Fujisawa; John J Castellot
Journal:  J Cell Commun Signal       Date:  2014-07-11       Impact factor: 5.782

Review 3.  Uterine leiomyomas revisited with review of literature.

Authors:  Rishi Philip Mathew; Swati Francis; Vinayak Jayaram; Shameema Anvarsadath
Journal:  Abdom Radiol (NY)       Date:  2021-05-31

4.  Oncogenic exon 2 mutations in Mediator subunit MED12 disrupt allosteric activation of cyclin C-CDK8/19.

Authors:  Min Ju Park; Hailian Shen; Jason M Spaeth; Jaana H Tolvanen; Courtney Failor; Jennifer F Knudtson; Jessica McLaughlin; Sunil K Halder; Qiwei Yang; Serdar E Bulun; Ayman Al-Hendy; Robert S Schenken; Lauri A Aaltonen; Thomas G Boyer
Journal:  J Biol Chem       Date:  2018-02-13       Impact factor: 5.157

Review 5.  The role of angiogenic factors in fibroid pathogenesis: potential implications for future therapy.

Authors:  Reshef Tal; James H Segars
Journal:  Hum Reprod Update       Date:  2013-09-29       Impact factor: 15.610

6.  Halofuginone suppresses growth of human uterine leiomyoma cells in a mouse xenograft model.

Authors:  Faezeh Koohestani; Wenan Qiang; Amy L MacNeill; Stacy A Druschitz; Vanida A Serna; Malavika Adur; Takeshi Kurita; Romana A Nowak
Journal:  Hum Reprod       Date:  2016-04-29       Impact factor: 6.918

Review 7.  Biomarkers in uterine leiomyoma.

Authors:  Gary Levy; Micah J Hill; Torie C Plowden; William H Catherino; Alicia Y Armstrong
Journal:  Fertil Steril       Date:  2012-11-29       Impact factor: 7.329

8.  Transforming growth factor-β signaling pathway cross-talking with ERα signaling pathway on regulating the growth of uterine leiomyoma activated by phenolic environmental estrogens in vitro.

Authors:  Yang Shen; Yanting Wu; Qing Lu; Peili Zhang; Mulan Ren
Journal:  Tumour Biol       Date:  2015-07-30

9.  Leiomyoma cells in 3-dimensional cultures demonstrate an attenuated response to fasudil, a rho-kinase inhibitor, when compared to 2-dimensional cultures.

Authors:  Minnie Malik; Joy Britten; James Segars; William H Catherino
Journal:  Reprod Sci       Date:  2014-08-01       Impact factor: 3.060

10.  Liarozole inhibits transforming growth factor-β3--mediated extracellular matrix formation in human three-dimensional leiomyoma cultures.

Authors:  Gary Levy; Minnie Malik; Joy Britten; Melissa Gilden; James Segars; William H Catherino
Journal:  Fertil Steril       Date:  2014-05-10       Impact factor: 7.329

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.